Brief: Sensei Biotherapeutics Announces Name Change To Faeth Therapeutics
BRIEF-Sensei Biotherapeutics Announces Name Change To Faeth Therapeutics June 15 (Reuters) - Sensei Biotherapeutics Inc SNSE.O:
SENSEI BIOTHERAPEUTICS ANNOUNCES NAME CHANGE TO FAETH THERAPEUTICS, FOCUSED ON ADVANCING PIKTOR, AN ORAL THERAPY TARGETING ONE OF THE MOST FREQUENTLY ALTERED PATHWAYS IN CANCER
SENSEI BIOTHERAPEUTICS - COMMON STOCK TO BEGIN TRADING AS FTH ON NASDAQ ON JUNE 16, 2026
SENSEI BIOTHERAPEUTICS - APPOINTS ANAND PARIKH AS CHAIRMAN, PRESIDENT AND CEO EFFECTIVE JUNE 12, 2026
SENSEI BIOTHERAPEUTICS - APPOINTS BRIAN STEPHENSON AS CHIEF FINANCIAL OFFICER
SENSEI BIOTHERAPEUTICS - PIKTOR PHASE 2 TOPLINE DATA IN ADVANCED ENDOMETRIAL CANCER EXPECTED SECOND HALF 2026
SENSEI BIOTHERAPEUTICS - PIKTOR PHASE 1B/2 INTERIM DATA IN HR+/HER2- ADVANCED BREAST CANCER EXPECTED IN 2027
Source text: ID:nBw48Dc9ra
Further company coverage: SNSE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Faeth Therapeutics
See all newsU.S. STOCKS ON THE MOVE - Nvidia, Gold miners, Nike
U.S. STOCKS ON THE MOVE - Sunrun, JetBlue Airways, Dell Technologies
Faeth Therapeutics rises after FDA grants fast-track status for cancer drug
Brief: Faeth Therapeutics Announces FDA Grant Of Fast Track Designation For Piktor Plus Paclitaxel In Biomarker-Selected Advanced Endometrial Cancer
Brief: Faeth Therapeutics Strengthens Executive Team With Senior Leadership Appointments